Yasuchika Hasegawa News
-
Takeda Pharmaceutical Co., Asia’s largest drugmaker, fell the most in more than four years in Tokyo trading after full-year operating profit missed its own forecast and analyst estimates.
-
Takeda Pharmaceutical Co. , Asia’s largest drugmaker, is seeking a 10-fold revenue gain in China within five years after hiring a top executive to stem an exodus of sales employees there, President Yasuchika Hasegawa said.
-
Takeda Pharmaceutical Co. President Yasuchika Hasegawa spent four years searching for an acquisition in Europe to revive growth. The result: Nycomed, a Swiss drugmaker with falling earnings and a $9.1 billion price tag.
-
Japan’s electricity curbs aimed at averting summertime outages will have “very minimal” impact on businesses, said Yasuchika Hasegawa , head of the Japan Association of Corporate Executives.
-
The following is a calendar of expected financial events in Japan. Other calendars can be found at: {ECO JN <GO>} for economic indicators, {ACDR <GO>} for earnings, and {CACT <GO>} for corporate actions. Times may change.
-
The following is a calendar of expected financial events in Japan. Other calendars can be found at: {ECO JN <GO>} for economic indicators, {ACDR <GO>} for earnings, and {CACT <GO>} for corporate actions. Times may change.
-
The following is a calendar of expected financial events in Japan. Other calendars can be found at: {ECO JN <GO>} for economic indicators, {ACDR <GO>} for earnings, and {CACT <GO>} for corporate actions. Times may change.
-
The following is a calendar of expected financial events in Japan. Other calendars can be found at: {ECO JN <GO>} for economic indicators, {ACDR <GO>} for earnings, and {CACT <GO>} for corporate actions. Times may change.
-
The following is a calendar of expected financial events in Japan. Other calendars can be found at: {ECO JN <GO>} for economic indicators, {ACDR <GO>} for earnings, and {CACT <GO>} for corporate actions. Times may change.
-
Takeda Pharmaceutical Co. is pursuing its biggest acquisition after destroying more value for shareholders than any drugmaker and hoarding the most cash.
|
|
Yasuchika Hasegawa Photos
Most Popular on Bloomberg
|
| |